Climb Bio (CLYM) analyst forecast and price target
Analyst forecast
Consensus of 16 analyst ratings
Based on 7 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $30.00 from $24.00 | Sep 8, 2026 |
| Oppenheimer | Maintained | Outperform | $25.00 from $18.00 | Sep 8, 2026 |
| B. Riley Securities | Maintained | Buy | $30.00 from $26.00 | Sep 4, 2026 |
| BTIG | Maintained | Buy | $32.00 from $20.00 | Sep 3, 2026 |
| Baird | Maintained | Outperform | $25.00 from $21.00 | Sep 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $24.00 from $20.00 | Aug 24, 2026 |
| Wedbush | Maintained | Outperform | $20.00 | Aug 19, 2026 |
| Truist Securities | Maintained | Buy | $25.00 from $17.00 | Aug 7, 2026 |
| Wedbush | Maintained | Outperform | $20.00 from $17.00 | Jul 27, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 | Jun 24, 2026 |
| Wedbush | Maintained | Outperform | $17.00 | Jun 12, 2026 |
| BTIG | Maintained | Buy | $20.00 from $19.00 | Jun 11, 2026 |
| BTIG | Maintained | Buy | $19.00 | Jun 8, 2026 |
| Guggenheim | Initiated Coverage | Buy | $35.00 | Jun 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20.00 from $15.00 | May 12, 2026 |
| Wedbush | Maintained | Outperform | $17.00 from $15.00 | May 8, 2026 |
| BTIG | Maintained | Buy | $19.00 from $8.00 | May 6, 2026 |
| Chardan Capital | Initiated Coverage | Buy | $22.00 | May 5, 2026 |
| Oppenheimer | Maintained | Outperform | $18.00 from $10.00 | Apr 21, 2026 |
| Mizuho | Initiated Coverage | Outperform | $18.00 | Apr 15, 2026 |
Frequently asked questions
What is the price target for CLYM stock?
The average 12-month analyst price target for Climb Bio (CLYM) is $26.71, with a high estimate of $32.00 and a low of $20.00, across 7 analysts.
Is CLYM a buy, sell, or hold?
Analysts covering Climb Bio currently average a Buy rating: 16 buy, 0 hold and 0 sell, from 16 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CLYM?
The average price target of $26.71 implies 144.86% upside from the last price of $10.91.
What is the latest analyst rating on CLYM?
On Sep 8, 2026, HC Wainwright & Co. maintained Climb Bio at Buy with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.